Navigation Links
AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation
Date:3/15/2011

SAN FRANCISCO, March 15, 2011 /PRNewswire/ -- AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC). The Phase III clinical programme is designed to investigate the safety and efficacy of NKTR-118 as a medicine to relieve opioid induced constipation, a common side effect of prescription opioids when used for chronic pain management.  NKTR-118 is part of the exclusive worldwide license agreement announced on September 21, 2009, between AstraZeneca and Nektar Therapeutics (NASDAQ: NKTR).

The Phase III clinical programme will consist of two 12-week, randomized, placebo-controlled efficacy studies (with approximately 630 randomized patients each) and an open-label, randomized, long-term safety study with a "usual care" comparator arm.  The 12 week efficacy studies will compare response rate among placebo and two different doses of NKTR 118 with primary endpoint at 4 weeks. There is a three month safety extension following one of the two 12 week studies.

The long-term safety study will include patients from the 12-week efficacy studies, as well as new patients not previously enrolled. All patients will be randomly assigned to open-label treatment of either NKTR-118 or physician's choice (usual care) laxative regimen.  Safety assessments will also be collected throughout the trials.

"This is a key milestone for NKTR-118," said Anders Ekblom, Executive Vice President of Global Medicines Development, AstraZeneca. "We will put our knowledge and our effort into studying NKTR-118 as a potential effective new treatment option for Opioid Induced Constipation, which continues to be an area of unmet need in patients needing effective pain treatment."

The first regulatory filings based on the programme are planned for 2013.

NOTES TO EDITORS:About NKTR-
'/>"/>

SOURCE AstraZeneca; Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)...  AbbVie (NYSE: ABBV ) will participate ... March 12, 2015. Richard A. Gonzalez , chairman ... and answer session at 8:30 a.m. Central time. ... be accessible through AbbVie,s Investor Relations Web site at ... will be available later that day. ...
(Date:3/6/2015)... Alemania, 6 de marzo de 2015 ... de gestión empresarial de imagen médica, fortalece su ... nombramiento de Randolph Sternberg como director ... como director de operaciones. Logo - ... será responsable de las ventas y desarrollo ...
(Date:3/5/2015)... 5, 2015   MeridianRx earned highest ... seven optional leading indicators during its recent URAC ... "We are very proud of earning this level ... , Chief Operating Officer of MeridianRx. "It is ... to transparency, flexibility and innovation." URAC,s ...
Breaking Medicine Technology:TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3MeridianRx Earns Highest URAC Accreditation Status 2
... May 4 With today,s announcement of a new ... leadership in health information technology (HIT) has now attracted $49.5 ... Reinvestment Act (ARRA). , , ... The latest grant comes through the Beacon Communities Cooperative Agreement ...
... NEW ORLEANS , May 4 ... with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 ...   Traficet-EN maintained a clinical remission rate (Crohn,s Disease ... in Crohn,s patients over the course of 36 weeks, ...
Cached Medicine Technology:Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 2Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 3Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 4ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 2ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 3ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 4ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 5ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 6
(Date:3/6/2015)... 2015 At Natural Products Expo ... the launch of its powerful, location-aware iOS app ... sustainable products at any retailer that carries those ... Expo West Booth 6054. , Makeena’s proprietary ... non-GMO, organic, Paleo, and vegan, among many other ...
(Date:3/6/2015)... La (PRWEB) March 06, 2015 Many ... function despite medical therapy. If you (or someone you ... to knee osteoarthritis, you may be interested in the ... Covington Orthopedic announced today that he is one of ... Cytori Therapeutics to begin enrolling subjects as part of ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 In a new ... Polish mesothelioma patients reported that shoulder pain was their first ... on its website. Click here to read it now. ... analyzed the medical records of 49 mesothelioma patients ... reported that it was shoulder pain that first prompted them ...
(Date:3/6/2015)... 06, 2015 Los Angeles cosmetic dentist ... for Zoom whitening. Zoom is a special type of teeth ... Unlike other teeth whitening treatments, Zoom does its job in ... stains. For a limited time, Dr. Ghasri is offering Zoom ... usual price of $650 and allows patients to try out ...
(Date:3/6/2015)... As the Mayo Clinic's 2012 published Benicar ... Associates Nationwide Legal Services, A.P.C., comments on these findings ... v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, in US ... light of a recently filed lawsuit, Ford & Associates ... explore the Mayo Clinic's Benicar case study findings purportedly ...
Breaking Medicine News(10 mins):Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, is Now Offering a Promotion on Zoom Whitening 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4
... the 1960s, surgeons experimented by transplanting chimpanzee organs into humans ... received a baboon heart and survived 20 days. // Since ... source for organs, tissues and cells to treat various diseases, ... the controversy surrounding cross-species transplant -- also known as xenotransplantation. ...
... diabetes is important because lifestyle changes and medication can prevent ... glucose tolerance test is used to identify high-risk individuals for ... study finds a cluster of risk //factors known as metabolic ... other risk factors. ,Metabolic syndrome has been shown ...
... osteoarthritis and rheumatoid arthritis cause joint pain and //stiffness ... no effective treatment to repair damaged cartilage. ... drug to prevent the onset of arthritis. The research ... a pivotal role in the onset of the condition. ...
... births of their first two children are more likely to deliver ... the same partner.// These babies are also ... results are the same even when researchers take into account the ... of birth. ,Researchers speculate that women who change ...
... the right mattress can make a difference. //Three-quarters of physicians ... a new study says they could be wrong. The new ... pain. ,Physicians often get frustrated when patients ask ... back pain. Few studies have been done on this issue ...
... night outlawed tobacco use in the Commonwealth's restaurants, taverns, ... on Sunday liquor-store sales as the House and Senate ... ,Working until nearly midnight, lawmakers also approved a sales ... thereby pumping up the state's flagging economy, and approved ...
Cached Medicine News:Health News:Animals Can give us a second chance at life 2Health News:Predictors for Type 2 Diabetes 2Health News:Changing Partners may put Expectant Mothers at Risk 2Health News:Senate assures ban on smoking 2Health News:Senate assures ban on smoking 3Health News:Senate assures ban on smoking 4
... Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No ... 0.2-2 Inaccuracy (%) ... Imprecision(%) ... 0.01 Dimensions: ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
Developed specifically for the 5000/5500 ultrasound consoles....
Medicine Products: